These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 15850334)

  • 21. Pattern of long-term sensorimotor recovery following intrastriatal and--accumbens DA micrografts in a rat model of Parkinson's disease.
    Falkenstein G; Rosenthal C; Reum T; Morgenstern R; Döbrössy M; Nikkhah G
    J Comp Neurol; 2009 Jul; 515(1):41-55. PubMed ID: 19399892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The subthalamic nucleus: a possible target for stereotaxic surgery in Parkinson's disease.
    Guridi J; Luquin MR; Herrero MT; Obeso JA
    Mov Disord; 1993 Oct; 8(4):421-9. PubMed ID: 8232351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat.
    Breit S; Bouali-Benazzouz R; Popa RC; Gasser T; Benabid AL; Benazzouz A
    Exp Neurol; 2007 May; 205(1):36-47. PubMed ID: 17395181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expression of the enzymes of dopamine synthesis in non-dopaminergic neurons: functional significance and regulation].
    Ugriumov MV
    Usp Fiziol Nauk; 2007; 38(4):3-20. PubMed ID: 18064905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of unilateral lesion of the nigrostriatal dopamine pathway on survival and neurochemistry of parafascicular nucleus neurons in the rat--evaluation of time-course and LGR8 expression.
    Sedaghat K; Finkelstein DI; Gundlach AL
    Brain Res; 2009 May; 1271():83-94. PubMed ID: 19328193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.
    Engler H; Doenlen R; Riether C; Engler A; Niemi MB; Besedovsky HO; del Rey A; Pacheco-López G; Feldon J; Schedlowski M
    Brain Behav Immun; 2009 May; 23(4):518-26. PubMed ID: 19486644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuronal cell replacement in Parkinson's disease.
    Hedlund E; Perlmann T
    J Intern Med; 2009 Oct; 266(4):358-71. PubMed ID: 19765180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease.
    Guridi J; Obeso JA; Rodriguez-Oroz MC; Lozano AA; Manrique M
    Neurosurgery; 2008 Feb; 62(2):311-23; discussion 323-5. PubMed ID: 18382309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered.
    Braak H; Del Tredici K
    Exp Neurol; 2008 Jul; 212(1):226-9. PubMed ID: 18501351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical treatment of Parkinson's disease.
    Krauss JK; Jankovic J
    Am Fam Physician; 1996 Oct; 54(5):1621-9. PubMed ID: 8857784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease?
    Do Thi NA; Saillour P; Ferrero L; Paunio T; Mallet J
    Gene Ther; 2007 Mar; 14(5):441-50. PubMed ID: 17093508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Movement disorders and basal ganglia function].
    Dietrichs E
    Tidsskr Nor Laegeforen; 2008 Sep; 128(17):1968-71. PubMed ID: 18787574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Striatal dysfunction increases basal ganglia output during motor cortex activation in parkinsonian rats.
    Belluscio MA; Riquelme LA; Murer MG
    Eur J Neurosci; 2007 May; 25(9):2791-804. PubMed ID: 17561844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies.
    Hodaie M; Neimat JS; Lozano AM
    Neurosurgery; 2007 Jan; 60(1):17-28; discussion 28-30. PubMed ID: 17228250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease.
    Bonsi P; Cuomo D; Picconi B; Sciamanna G; Tscherter A; Tolu M; Bernardi G; Calabresi P; Pisani A
    Amino Acids; 2007 Feb; 32(2):189-95. PubMed ID: 16715415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene therapy for Parkinson's disease.
    Lawlor PA; During MJ
    Expert Rev Mol Med; 2004 Mar; 6(5):1-18. PubMed ID: 15000692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electrophysiological targeting in stereotaxic surgery for Parkinson's disease.
    Macias R; Teijeiro J; Torres A; Alvarez L
    Adv Neurol; 1997; 74():175-82. PubMed ID: 9348413
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of surgery targeting the caudal intralaminar thalamic nuclei on the pathophysiological functioning of basal ganglia in a rat model of Parkinson's disease.
    Kerkerian-Le Goff L; Bacci JJ; Jouve L; Melon C; Salin P
    Brain Res Bull; 2009 Feb; 78(2-3):80-4. PubMed ID: 18790021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cell therapy and other neuroregenerative strategies in Parkinson's disease (II)].
    Mínguez-Castellanos A; Escamilla-Sevilla F
    Rev Neurol; 2005 Dec 1-15; 41(11):684-93. PubMed ID: 16317638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.